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Abstract To report long-term results for children with
low-grade hypothalamic/chiasmatic gliomas treated on a
phase II chemotherapy protocol. Between 1984 and 1992,
33 children with hypothalamic/chiasmatic LGGs received
TPDCV chemotherapy on a phase II prospective trial.
Median age was 3.0 years (range 0.3–16.2). Twelve
patients (36%) underwent STRs, 14 (42%) biopsy only, and
seven (21%) no surgery. Twenty patients (61%) had
pathologic JPAs, nine (27%) grade II gliomas, and four
(12%) no surgical sampling. Median f/u for surviving
patients was 15.2 years (range 5.3–20.7); 20 of the 23
surviving patients had 14 or more years of follow-up.
Fifteen-year PFS and OS were 23.4 and 71.2%, respec-
tively. Twenty-ﬁve patients progressed, of whom 13 are
NED, two are AWD, and 10 have died. All children who
died were diagnosed and ﬁrst treated at age three or
younger. Age at diagnosis was signiﬁcantly associated with
relapse and survival (P = 0.004 for PFS and P = 0.037 for
OS). No PFS or OS beneﬁt was seen with STR versus
biopsy/no sampling (P = 0.58 for PFS, P = 0.59 for OS).
For patients with JPAs and WHO grade II tumors, the 15-
year PFS was 18.8 and 22.2% (P = 0.95) and 15-year OS
was 73.7 and 55.6% (P = 0.17), respectively. Upfront
TPDCV for children with hypothalamic/chiasmatic LGGs
resulted in 15-year OS of 71.2% and 15-year PFS of
23.4%. No survival beneﬁt is demonstrated for greater
extent of resection. Age is a signiﬁcant prognostic factor
for progression and survival.
Keywords Low-grade gliomas  Pediatric 
Chemotherapy  Radiation  Hypothalamic/chiasmatic
Abbreviations
WHO World Health Organization
LGG Low-grade glioma
PFS Progression-free survival
OS Overall survival
GTR Gross total resection
STR Subtotal resection
UCSF University of California San Francisco
RT Radiation therapy
NED No evidence of disease
AWD Alive with disease
HR Hazard ratio
JPA Juvenile pilocytic astrocytoma
OPG Optic pathway glioma
BTRC Brain Tumor Research Center
KPS Karnofsky Performance Score
COG Children’s Oncology Group
VEGF Vascular endothelial growth factor receptor
MAPK Mitogen-activated protein kinase
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The treatment of hypothalamic/chiasmatic LGGs repre-
sents a unique clinical challenge because involvement of
eloquent midline structures frequently precludes extensive
resection of these tumors. Radiation can effectively reduce
tumor bulk and slow or halt progression of pediatric mid-
line LGGs; however it can also lead to long-term compli-
cations including neurocognitive deﬁcits, hormonal
changes, growth delay, and radionecrosis [1, 2]. In an effort
to defer radiation, upfront chemotherapy has been studied
for the treatment of hypothalamic/chiasmatic LGGs [2, 3].
Although overall survival (OS) rates for pediatric optic
pathway gliomas are excellent (5-year OS of 80–90%), the
majority of children (60–70%) initially managed with
chemotherapy will experience disease progression [4].
Due to limited number of cases, differences in treatment
regimens, dearth of randomized studies, and often inade-
quate follow up, a lack of consensus persists regarding the
optimal treatment of pediatric hypothalamic/chiasmatic
LGGs. In 1984, we instituted a study protocol at the Uni-
versity of California San Francisco—Brain Tumor
Research Center (UCSF-BTRC) to evaluate the efﬁcacy of
upfront chemotherapy alone for treatment of hypothalamic/
chiasmatic LGGs in our pediatric population. BTRC pro-
tocol 8422 was a planned phase II prospective trial eval-
uating TPDCV chemotherapy in children age 18 and
younger. TPDCV is a ﬁve-drug regimen consisting of 6-
thioguanine, procarbazine, dibromodulcitol, 1-(2-chloro-
ethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine
and described in detail in the original publication [5, 6].
This report updates the follow-up on the subset of pediatric
patients with hypothalamic/chiasmatic LGGs who were
treated with an outpatient upfront TPDCV chemotherapy
regimen alone and no radiation at the time of initial
treatment.
Materials and methods
Between March 9, 1984 and January 29, 1992, 33 children
ages 18 and younger with low-grade (WHO grade I and II)
hypothalamic/chiasmatic gliomas were enrolled on UCSF-
BTRC protocol 8422, a single arm phase II prospective
trial. On this protocol, patients received outpatient TPDCV
chemotherapy as their primary treatment (details of the
protocol have been previously published, see [5, 6]). All
patient characteristics, treatment parameters, and survival
data were extracted from clinical records, radiographic
information, and active follow-up obtained from the
Departments of Radiation Oncology, Neuro-oncology, and/
or Neurosurgery at UCSF. Informed consent was obtained
from parents or guardians of each child before entry into
the trial. This study was performed after approval by local
Human Investigations Committees.
Subjects’ original pathological diagnoses from UCSF
neuropathology were used for classiﬁcation. Tumor types
included low-grade astrocytoma, oligodendroglioma, and
mixed oligoastrocytoma. Histopathologic conﬁrmation of
the diagnosis was required in all patients except those with
diffusely inﬁltrating diencephalic lesions who had neuro-
ﬁbromatosis and those with optic chiasm lesions extending
posteriorly along the optic radiations or causing enlarge-
ment of the optic nerves.
Extent of resection was based on pre- and post-operative
radiographic imaging studies as well as operative reports.
There were no gross total resections (GTRs) in the study
population. Subtotal resection (STR) included those with
bulk tumor resection and residual tumor on radiographic
imaging; biopsy included those with surgical tumor sam-
pling only for sole purpose of histologic diagnosis.
Chemotherapy details are outlined in previous reports
[5, 6]. Brieﬂy, a nitrosourea based multi-agent chemo-
therapy was given as follows. TPDCV chemotherapy
cycles consisted of 6-thioguanine (hour 0–66), procarba-
zine (hour 60–78), and dibromodulcitol (hour 60) given
before lomustine (CCNU; hour 72); vincristine was then
given after CCNU (day 14 and 28). Dosing was as follows:
6-thioguanine 30 mg/m
2 orally every 6 h 9 12 doses,
procarbazine 50 mg/m
2 orally every 6 h 9 4 doses, dib-
romodulcitol 400 mg/m
2, CCNU 110 mg/m
2, vincristine
1.4 mg/m
2 IV push. Each cycle was planned at 42-day
intervals. Patients were treated for six treatment cycles or
until tumor progressed, whichever came ﬁrst. Chemother-
apy was modiﬁed based on hematologic and other agent-
speciﬁc toxicities. Dose escalations were not allowed.
No child received up-front radiation as part of his/her
primary treatment. Patients with prior radiation or che-
motherapy were excluded. The decision of whether to
administer radiation or other treatment modalities as sal-
vage therapy was made at the discretion of the treating
physician.
During the follow-up period, information regarding
clinical status, radiographic status, salvage therapies, pro-
gression, and survival were noted. Patients underwent
contrast-enhanced MRI or CT imaging within 2 weeks
before study entry and thereafter every 6 weeks during
treatment. During the follow-up period, stable and
responding patients underwent MR or CT imaging every
3 months for the ﬁrst year, every 4 months the second year,
every 6 months the third year, then annually, and if stable
had scans at 1–3 year intervals thereafter.
PFS and OS rates were calculated from date of diag-
nosis. Life-table methods were used to estimate PFS and
OS [7]. Five- and 10-year PFS and OS estimates were
calculated using the Kaplan–Meier method, with standard
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123errors calculated by Greenwood’s formula. Elapsed time
from diagnosis to an event or last follow-up was used to
compute PFS and OS probabilities. In analyses of PFS, last
follow-up dates for patients not experiencing an event were
based on most recent clinical and/or radiographic follow-
up that delineated disease status. For OS, deaths, regardless
of cause, were coded as events. For PFS, an event was
deﬁned as relapse, progression or death during the period
of active follow-up. To assess variables inﬂuencing PFS
and OS, univariate analyses using log-rank tests and pro-
portional hazards models were performed.
Results
Demographics
Thirty-three patients were enrolled in UCSF-BTRC phase
II protocol 8422 between 1984 and 1992. Median age at
diagnosis was 3.0 years (range 0.3–16.2 years). The ratio
of female to male was 20:13 (61:39%); six patients (18%)
were diagnosed with neuroﬁbromatosis. Tumor location
was classiﬁed as hypothalamic or chiasmatic in 27 and 6
patients (82 and 18%), respectively. The median Karnofsky
Performance Score (KPS) at diagnosis was 80 (range 70–
100). No patient had a GTR, 12 patients (36%) underwent
STR, and 14 (42%) had biopsy at the time of diagnosis.
Seven patients (21%) had no surgery at time of diagnosis,
of which three had subsequent surgery at the time of
recurrence. Twenty patients (61%) had pathologic JPAs, 9
patients (27%) had grade II gliomas, and 4 patients (12%)
had no surgical sampling. Table 1 summarizes the clinical
characteristics for the entire cohort.
Follow Up
Median follow-up for surviving patients was 15.2 years
(range 5.3–20.7 years). All but three of the surviving
patients had 14 or more years of follow-up with regular
interval radiographic scans. All surviving patients had at
least 5 years of follow-up. Two patients had clinical fol-
low-up of NED status however their most recent MRI/CT
scan was dated more than 3 years prior to date of last
clinical follow-up. Three patients were lost to follow-up
after 5.3, 6.5, and 9.3 years, respectively, of follow-up. Of
these three patients, the ﬁrst had progressed at 3.9 years but
salvage therapy was given elsewhere and no further records
could be located.
Overall PFS and OS
Median PFS was 3.1 years, median OS has not been
reached. Five-year PFS and OS were 30.3 ± 8.0 and
90.9 ± 5.0%, respectively. Fifteen-year PFS and OS were
23.4 ± 7.6 and 71.2 ± 8.1%, respectively. Figures 1 and 2
showtheKaplan–MeiercurvesforPFSandOS,respectively.
Twenty-ﬁvepatientsprogressedduringthefollow-upperiod
and underwent subsequent radiation, chemotherapy, and/or
surgical salvage. All but one progression event occurred
within six years of diagnosis. For the patients that died,
medianPFSwas1.9 years(range0.6–5.7 years)andmedian
OS was 6.6 years (range 2.1–15.4 years). Of the 11 patients
Table 1 Patient characteristics and treatment details
Variables Total (N = 33)
Age—median (range), years 3.0 (0.3–16.2)
Follow-up—median (range)
a, years 15.2 (5.3–20.7)
Pts with C5 years of follow-up/total surviving pts 23/23 (100%)
Gender—Female:male (%) 20:13 (61:39%)
Tumor location—hypothalamic: chiasmatic 27:6 (82:18%)
Neuroﬁbromatosis 6 (18%)
KPS, median (range) 80 (70–100)
Histology: JPA 20 (61%)
Grade II LGG 9 (27%)
No histologic sampling 4 (12%)
Extent of resection at diagnosis
Gross total resection 0
Subtotal resection 12 (36%)
Biopsy only 14 (42%)
No surgery
b 7 (21%)
a Follow-up for surviving patients
b Three of these 7 patients had surgery at time of progression
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Fig. 1 Progression-free survival of 33 patients on phase II TPDCV
chemotherapy trial for pediatric low-grade hypothalamic/chiasmatic
gliomas
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123who had surgery as part of their salvage therapy, seven
recurred as low grade gliomas (six JPAs and one low grade
astrocytoma). For the four others, pathology was not avail-
able. All children who have died were diagnosed and ﬁrst
treated at age 3 or younger.
Given the use of an alkylator-based regimen inthis study,
we speciﬁcally inquired about the development of second-
ary malignancies. One patient developed a second primary
many years after therapy, an osteosarcoma that arose within
the radiation ﬁeld. This patient was a Caucasian female with
a grade II hypothalamic tumor diagnosed at age 2.3 years;
she did not have neuroﬁbromatosis. She had received che-
motherapy upfront according to protocol guidelines and
then radiation to 54 Gy for ﬁrst salvage and procarbazine
for second progression. She died due to progression of her
secondary sarcoma 15.4 years after her primary diagnosis.
Salvage therapy
Twenty-ﬁve patients progressed during the period of active
follow-up. Of these 25, 13 are salvaged and currently NED
with a median follow-up of 15.5 years. Two are alive with
disease, and 10 are dead at last follow-up. Of the 25
patients who progressed, 24 had their ﬁrst progression
event within 6 years of diagnosis. Salvage therapy at time
of ﬁrst progression included radiation (RT; N = 17), che-
motherapy (N = 8), and surgery (N = 11). Table 2 sum-
marizes the salvage therapies utilized and number of
patients currently NED according to salvage treatment
modality. Of note, one patient who progressed during his
TPDCV chemotherapy regimen was salvaged with single
agent carboplatin and is currently NED with last follow-up
at 15.2 years since diagnosis.
Seventeen of the 25 patients who progressed underwent
subsequent radiation as part of their salvage therapy. The
vast majority received a total dose of 50.4–54 Gy in 1.8–
2 Gy fractions to the primary tumor site with margin. One
patient received hyperfractionated RT (1.15 Gy BID to
63.4 Gy) and two patients received stereotactic radiosur-
gery as part of their radiation course. A total of seven
patients of the 17 undergoing subsequent RT were suc-
cessfully salvaged and NED at last follow-up.
Prognostic factors
Age
Eighteen children enrolled on study were 3 years or
younger at diagnosis (‘‘young children’’) and 15 were older
than 3 years at diagnosis (‘‘old children’’). A total of 10
young children died, 7 remained NED, and 1 was AWD at
last follow-up. Age at diagnosis was signiﬁcantly associ-
ated with OS (P = 0.037). All ten children that died in the
entire study cohort were 3 years of age or younger at
diagnosis. For the children that died, median PFS was
1.9 years (range 0.6–5.7) and median OS was 6.6 years
(range 2.1–15.4).
Progression occurred more frequently and earlier in the
B3 year old group, with 17 of 18 progressing among young
patients versus eight of 15 progressing among older chil-
dren. Age at diagnosis was signiﬁcantly associated with
PFS (P = 0.004); with a median PFS of 2.6 versus
6.6 years for the young versus old group, respectively.
Of the 17 progressing young children, 13 underwent RT
as part of their salvage therapy with eight dead at last
follow-up; and four received chemotherapy and/or surgical
salvage, of who two died. Of the 13 young children that
underwent salvage RT, the average delay until RT was
given from time of diagnosis was 2.7 years. For 10 of the
13, radiation delivery was successfully delayed until after
the age of 3. Three children underwent salvage RT before
turning 3 years of age at age 2.9, 2.7, and 1.5 and at last
follow-up are DOD, NED, and DOD, respectively.
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Fig. 2 Overall survival of 33 patients on phase II TPDCV chemo-
therapy trial for pediatric low-grade hypothalamic/chiasmatic gliomas
Table 2 Components of salvage therapy and no-evidence-of-disease
(NED) status
Total salvage therapy Number
of pts
Number NED
RT alone 7 3
Chemotherapy alone 2 1
Surgery alone 2 2
RT ? chemo 3 1
RT ? surgery 6 3
Chemotherapy ? surgery 2 1
RT ? chemotherapy ? surgery 1 0
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Overall, no PFS or OS beneﬁt was seen with STR versus
biopsy/no sampling (P = 0.58 for PFS, P = 0.59 for OS).
During the follow-up period, progression occurred in 16 of
21 (76%) patients with biopsy or no surgical sampling and
nine of 12 (75%) patients with STRs. Death occurred in
three of 21 (33%) patients with biopsy or no surgical
sampling and three of 12 (25%) patients with STRs.
Median PFS was 2.0 versus 3.6 years for patients with
STRs versus biopsy/no sampling (P = ns).
Role of histologic subtype
Sixteen of 20 patients with JPAs progressed, of whom 10
were NED, one AWD, and ﬁve were dead of disease at last
follow-up. Seven of nine patients with WHO grade II
tumors progressed, of whom one was NED, one AWD, and
ﬁve were dead of disease at last follow-up. For patients
with JPAs and WHO grade II tumors, the 15-year PFS was
18.8 and 22.2% (P = 0.95) and 15-year OS was 73.7 and
55.6% (P = 0.17), respectively. Overall, no statistically
signiﬁcant difference was seen in PFS or OS between grade
I and II tumors.
Other factors including KPS, location, sex, and neuro-
ﬁbromatosis were not found to be statistically associated
with survival or relapse.
Discussion
Radiation historically had been a mainstay of treatment for
pediatric hypothalamic/chiasmatic LGGs. However, given
neurocognitive, endocrine, secondary malignancy, and
other long-term consequences, there has been a movement
towards attempting to treat children with upfront chemo-
therapy thus deferring or avoiding radiation [2, 3]. Various
systemic chemotherapy regimens have been studied by
investigators with the goal of potentially delaying and
perhaps obviating the need for radiation. In this manuscript
we report long-term results for 33 patients with hypotha-
lamic/chiasmatic LGGs treated on a phase II TPDCV
chemotherapy study. To our knowledge, this is the longest
follow-up available in the literature of a phase II chemo-
therapy trial for pediatric patients with hypothalamic/chi-
asmatic tumors.
One of the earliest series of chemotherapy for the
management of pediatric low-grade gliomas was published
by Packer et al. and reported results of using concurrent
carboplatin and vincristine. PFS rates were 75% at 2 years
and 68% at 3 years [8, 9].
During this same time period UCSF initiated the study
described herein using TPDCV. The original publication
focused on chiasmal/hypothalamic gliomas and enrolled 19
children ranging in age from 15 weeks to 15.6 years
(median 3.2 years) [6]. At a median follow-up of
79 weeks, median time to tumor progression had not been
reached and there were no tumor-related deaths. The four
patients who failed chemotherapy were treated satisfacto-
rily with radiation. Of the 18 evaluable patients, 16 had
initial improvement of stabilization of visual function.
UCSF investigators reported on an expanded cohort of
LGG patients, not limited to OPGs, treated with TPDCV.
Of the 42 children in this study, only eight had died, with
an estimated 5-year survival of 78%. Twenty-six patients
experienced tumor progression and median time to treat-
ment failure was 132 weeks [5].
The long-term results for 33 patients with chiasmal/
hypothalamic gliomas treated to date on this Phase II study
are reported herein. Our study shows favorable OS results,
with a 5-year OS of 90.9% and 15-year OS of 71.2%
indicating that salvage therapy consisting of radiation,
surgery, and/or chemotherapy is successful in many
patients.
Our 5-yearPFS is30.3% and15-yearPFS is23.4%.Most
patients (24 of 25 patients who progressed) had their ﬁrst
progression event within 6 years of diagnosis. Others have
found relapses commonly within the ﬁrst 5 years after
diagnosis as well [10]. Salvage therapy varied greatly and
included single or combined modality therapy with RT,
chemotherapy, and/or surgery. For most young patients,
salvageradiationcouldbedelayeduntilaftertheageofthree.
However, younger patients had much poorer prognosis
andmanycouldnotbesuccessfullysalvaged.All10patients
that died in our cohort were 3 years old or younger at diag-
nosis. Younger age was signiﬁcantly associated with poorer
OSandPFS(P = 0.037,P = 0.004,respectively).Ofthe18
children who were 3 years or younger at diagnosis, 17 pro-
gressed and of these, 10 died. Comparatively, of 15 children
who were older than 3 years at diagnosis, eight progressed
and none died. Similarly, young age has been found to be
associated with poorer outcome by many authors, including
four prospective and two retrospective studies [11].
In our study, extent of resection and histology showed
no statistically signiﬁcant beneﬁt in terms of PFS or OS.
Based on our data, combined with the majority of pub-
lished literature, there is no strong evidence that greater
extent of resection, without other purpose such as relief of
clinical symptoms, is indicated [11].
The regimen reported in this study constitutes one arm
of a large scale, randomized phase III, Children’s Oncol-
ogy Group study (COG A9952) examining the relative
effectiveness of carboplatin and vincristine (CV) versus
TPCV for children \10 years of age with progressive or
symptomatic unresectable LGGs. Tumor response rates for
non-NF1 associated tumors were 57% for CV and 58% for
J Neurooncol (2010) 100:121–127 125
123TPCV and median time to progression was 3.2 and
4.9 years for the two regimens, respectively [4]. Five-year
EFS in non-NF1 randomized subjects was 35 ± 4.8% for
CV versus 48 ± 4.8% for TPCV (P = 0.11). Five-year OS
for children with non-NF1 associated tumors was
86 ± 2.4% and there were no treatment-related deaths or
second malignant neoplasms [4]. These results are com-
parable to those reported herein, although with 15 year
follow up, it is apparent that the vast majority of children
experience disease progression and require salvage ther-
apy, most commonly including radiation therapy. A phase
II trial (ACNS0223) studied a similar patient subset as
A9952 with the addition of temozolomide to CV; the
results of this study are pending.
As chemotherapy is increasingly administered in an
effort to delay or avoid radiation we must bear in mind that
radiation utilized in our study cohort is outdated in many
cases and more conformal therapies are now available. In
the currently open Phase II COG trial ACNS0221 children
aged 3–21 years old with LGGs who have progression or
less than a GTR are treated with conformal radiotherapy
(3-D, intensity modulated therapy, protons, or stereotactic
radiosurgery) to a dose of 54 Gy. This study also has a
quality of life component and may eventually provide
better guidance as to the optimal use of modern radiation
treatment as part of LGG therapy.
Although TPDCV chemotherapy effectively delayed the
need for potentially morbid interventions such as surgery
and radiation, the long-term PFS of only 23.4% highlights
the need for systemic agents that can be administered
chronically with limited side-effects. Molecularly targeted
agents offer such promise and have now entered clinical
practice. For example, recent studies have shown that
aberrant activation of the mitogen-activated protein kinase
(MAPK) pathway due to gene duplication or activating
mutation of BRAF are a common event in the tumorigen-
esis of pediatric low-grade astrocytomas. Implication of
this signaling cascade in the molecular pathogenesis of
pediatric LGGs has opened new avenues for treatment and
inhibitors of the MAPK pathway are being proposed for
this patient population [12–14]. Similarly, laboratory evi-
dence demonstrating overexpression of vascular endothe-
lial growth factor receptor (VEGF) in pediatric LGGs has
led to the use of VEGF inhibitors with promising pre-
liminary results in multiply recurrent pediatric LGGs [15].
In this age of many potential systemic agents, some
more toxic than others, it should be noted that for patients
who are asymptomatic at presentation, one may consider
observation with regular scans, reserving intervention for
those who develop clinical signs or symptoms or evidence
of progression. Conversely, patients presenting with acute
symptoms may require immediate debulking and/or
radiation.
In conclusion, long-term outcomes for children with
hypothalamic/chiasmatic LGGs treated with upfront
TPDCV chemotherapy on a UCSF-BTRC phase II protocol
show a survival rate of 71.2% at 15-years follow-up. Most
patients who will progress do so within the ﬁrst six years
after diagnosis. Young children present a great clinical
challenge as their survival and progression prognosis are
poor. All 10 children who died in our cohort were 3 years
or younger at diagnosis.
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